|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Biognosys Partners With Kymera Therapeutics in Precision Proteomics Biomarkers |
 |
|
Biognosys’ TrueSignature™ proteomics panels serve as pharmacodynamic readout for protein degradation in Kymera’s discovery and clinical trial programs
March 15, 2022 – ZURICH – Business Wire. Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.
Proteome editing with TPD is a new frontier of medicine, aimed at expanding the druggable proteome. Biognosys’ TrueSignature™ platform uniquely offers high-precision proteomic panels that provide actionable insights based on highly specific and sensitive, absolute quantification of pharmacodynamic and efficacy biomarkers. These custom panels allow Kymera to monitor and quantify protein degradation. The ease of transferability of the assays — from early discovery, across preclinical evaluation, to clinical development — enables integration into all stages of Kymera’s drug development process. The panels are developed and performed at Biognosys’ state-of-the-art facility, the largest high-end, GLP certified and GCP compliant mass spectrometry laboratory worldwide for large-scale proteomics contract research.
“Kymera’s novel approach to targeted protein degradation is a great example of the power of proteomics-enabled drug development,” said Kristina Beeler, Ph.D., Chief Business Officer of Biognosys. “We are glad to see the impact our TrueSignature platform is having, not only on the advancement of Kymera’s clinical trial programs, but also on patients’ lives.”
The current partnership between Kymera and Biognosys builds upon the longstanding scientific relationship between the two companies across early R&D, preclinical, and clinical settings across oncology and inflammation.
“Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications,”said Nello Mainolfi, Ph.D., Co-Founder, President and CEO, Kymera Therapeutics. “The company’s high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs.”
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
New BHM® Anti-Viral Nasal Spray Launches in Singapore
Birmingham, UK, 28th April 2022 / Sciad Newswire / Birmingham
Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays
and mobile medical facilities, today announces the Singapore launch of
its latest technology, BHM® Anti-Viral Nasal Spray, an easy-to-use nasal
device with a unique patented formulation, Norizite™, designed to help
prevent infection from the inhalation of airborne viruses within the
nasal passages. The product will be available in Singapore from 1st May.
More info >> |
|
 |
White Papers |
 |
|
Assessing the Integrity of Pharmaceutical Packaging Using the Sepha Blisterscan and Conventional Blue Dye Leak Testing Methods
Sepha Limited
A new whitepaper by a leading packaging expert from the University of Ulster, Dr Dorian Dixon, into the integrity of pharmaceutical packaging has established that existing methods for testing the seal integrity of blister packs are not as accurate as newer, technology based test equipment.
More info >> |
|
|
